Drug Trial Radar · NCT07565285
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Dec 2027
Study completion Jun 2029
Sponsor
- Lead sponsor
- Primmune Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, multi-center, single-arm study evaluates the safety, tolerability, and activity of neoadjuvant PRTX007 in combination with pembrolizumab in participants with resectable Stage III melanoma. Neoadjuvant immunotherapy has demonstrated improved clinical outcomes compared with adjuvant-only approaches, but there remains a need to enhance pathologic response rates without significant added toxicity. Participants will receive oral PRTX007, a Toll-like receptor 7 (TLR7) agonist prodrug, administered in combination with intravenous pembrolizumab prior to surgical resection. The primary objective is to determine the major pathologic response (MPR) rate following neoadjuvant therapy. Secondary objectives include evaluation of safety, pathologic complete response, event-free survival, overall survival, pharmacokinetics, and immune-related biomarkers. This study aims to determine whether the addition of PRTX007 to pembrolizumab improves antitumor immune responses and clinical outcomes in patients with Stage III melanoma.
Conditions
- Melanoma Stage III
Interventions
PRTX007Drug
PRTX007 is an orally administered prodrug of PRX034, a Toll-like receptor 7 (TLR7) agonist designed to activate innate and adaptive immune responses. NEOADJUVANT REGIMEN * 600 mg orally once daily (safety run-in participants) or * 750 mg orally once daily (subsequent participants) * Administered 3 days on, 4 days off (7-day cycle) * Total of 9 cycles (9 weeks) ADJUVANT REGIMEN (IF NO MPR) * 750 mg orally once daily * Administered 3 days on, 4 days off * Total of 12 cycles (12 weeks)
PembrolizumabDrug
Pembrolizumab is a programmed cell death protein-1 (PD-1) blocking antibody administered by intravenous infusion NEOADJUVANT REGIMEN * 200 mg IV every 3 weeks (Q3W) * Total of 3 cycles (9 weeks) ADJUVANT REGIMEN * 400 mg IV every 6 weeks (Q6W) for 7 cycles OR * 200 mg IV every 3 weeks (Q3W) for 14 cycles * Total duration: approximately 42 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathologic Response (MPR) RateTime frame: At time of surgical resection (approximately 9 weeks after initiation of treatment)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Cairns And Hinterland Hospital And Health Service
Cairns, Queensland, Australia · Not yet recruiting
Gallipoli Medical Research
Greenslopes, Queensland, Australia · Not yet recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Not yet recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
One Clinical Research Pty Ltd
Nedlands, Western Australia, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.